Try our Advanced Search for more refined results

In Re: Actos Direct Purchaser Antitrust Litigation

  1. January 29, 2020

    Takeda Gets Go-Ahead To Appeal Actos Rulings At 2nd Circ.

    A New York federal judge has given pharmaceutical firm Takeda permission to appeal to the Second Circuit two decisions that preserved allegations it delayed the entry of generic alternatives to diabetes treatment Actos.

  2. December 16, 2019

    Actos Buyers Fight Takeda Appeal Bid In Drug Delay Case

    End payors and direct buyers of the diabetes drug Actos have urged a New York federal judge to nix Takeda's bid to immediately appeal her decision preserving some class action claims against the drugmaker, which they have accused of using patent suits to hold off generic competitors.

  3. November 25, 2019

    Takeda Wants Immediate Appeal Of Actos Order 'Uncertainty'

    Takeda has urged a New York federal judge to permit immediate appeal of two orders preserving some antitrust claims accusing the Japanese pharmaceutical company of delaying generic competition for its diabetes drug Actos, arguing that the court's interpretation of patent disclosure requirements upends government interpretation and "long-standing industry practice."

  4. October 08, 2019

    Takeda Avoids Most Claims In Actos Buyers' Antitrust Suit

    Japanese pharmaceutical company Takeda scored a big win Tuesday when a New York federal judge agreed to dismiss all claims but one in a suit accusing the company of delaying generic competition for its diabetes drug Actos.

  5. June 01, 2017

    Actos Buyers Fight To Preserve Market-Exclusivity Suit

    A proposed class of purchasers of diabetes drug Actos urged a New York federal judge Thursday to keep alive their suit claiming Takeda Pharmaceutical Company Ltd. misrepresented certain patents in an attempt to extend market exclusivity, saying they sufficiently alleged antitrust misconduct and bad faith.

  6. May 08, 2017

    Takeda, Generics Push To Toss Actos Buyers' Antitrust Suit

    Takeda and four generic-drug manufacturers told a New York federal court Friday to dismiss antitrust claims brought by a proposed class that bought diabetes drug Actos, saying that the purchasers' most recent changes to their claims are "purely cosmetic" and can't save the suit.